Abstract
Introduction
The report provides a comprehensive financial and strategic analysis of the
mAb market, forecasting its commercial evolution out to 2013 and assessing
trends by product, company, therapy area, technology and target type. It also
provides an insight into the direction of mAb technology evolution and an
analysis of pipeline dynamics.
Scope
- Comprehensive financial strategic analysis of the mAb market out to 2013
- Global sales forecasts to 2013 for marketed and Phase III mAb products
- Analysis of market trends by product, company, therapy area, technology
and target type
- Analysis of characteristics of key products and insight into direction of
mAb technology evolution and pipeline dynamics
Highlights
The overall prescription pharmaceutical market is expected to face a decline
in sales over 2011 to 2012 as a result of the ' patent cliff' . The patent cliff
will impact the small molecule market, in contrast, the mAb market segment
will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy
double-digit growth while small molecule drugs face declining growth rates.
The main barrier to sales growth for small molecules is exposure to material
generic competition, which will have no effect on mAbs out to 2013.
mAbs currently command a three-fold average revenue per product premium over
small molecules. Positive factors supporting this premium include a higher
demand due to addressing therapy areas of high unmet need and lower
competitive intensity due to accessing novel target space.
Reasons to Purchase
- Assess the key products that will drive sales growth in the mAb market to
2013
- Understand the challenges and barriers to entry for new players seeking to
venture into the mAb market
- Understand the nature of the generic threat across different molecule
types and the insulation of mAb products from biosimilars
View Cart
